November 1, 2025, marks the 9th "Shenzhen Talent Day" and the 7th "Shenzhen Entrepreneurs Day." Futian District specially hosted the "Celebrating Endeavor - Fu Opens the Future" Talent Day and Entrepreneurs Day event to pay tribute to the vast pool of talents and entrepreneurs within the district. Dr. Haisheng Zhang, founder and CEO of Signet Therapeutics, was invited to attend the event and received an honorary plaque jointly awarded by the Futian District Committee of the Communist Party of China and the People's Government of Futian District, Shenzhen.
With its outstanding performance in the biopharmaceutical field, continuous innovation capabilities, and significant contributions to regional innovation development, Signet Therapeutics was awarded the title of "Emerging Star Enterprise."
Dr. Zhang Haisheng, the founder and CEO of the company, was awarded the title of "Pioneer of Dedication" for his outstanding strategic vision, exceptional leadership, and contributions to the innovation and development of biomedicine.
Signet Therapeutics is an innovative targeted drug research and development company based in the Futian District's He Tao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone. It is a pioneer in the global "organoid + AI"-powered innovative targeted drug R&D model. The company has developed SIGX1094R, the world’s first targeted drug for diffuse gastric cancer, using its organoid + AI platform, which has now entered Phase I clinical trials.
This recognition from the Futian District Committee of the Communist Party of China and the Futian District People's Government of Shenzhen City encourages SIGNET to continuously explore new models and possibilities in biopharmaceutical R&D innovation, contributing to the realization of Futian's vision of becoming a "pioneer district with happy citizens" and supporting Shenzhen in building a more globally influential economic hub.
About SIGNET
SIGNET is a global pioneer in the "organoid + AI"-powered innovative targeted drug R&D model, and is a national high-tech enterprise as well as a specialized and new enterprise. The company's founding team consists of top talents from prestigious institutions such as Harvard University, MIT, and the Chinese Academy of Sciences. As first/corresponding authors, they have published more than 20 groundbreaking research papers in the field of gastric cancer and esophageal cancer in journals with impact factors over 20, such as Nature, Nature Medicine, and Cancer Cell, making them a global leader in gastric and esophageal cancer research. Since its establishment in Shenzhen at the end of 2020, the company has completed nearly 220 million yuan in financing and project funding, and holds more than 40 core intellectual properties.
The company currently has four first-in-class drug pipelines and one organoid platform in its portfolio. Its core pipeline, SIGX1094R, is the world's first targeted drug for diffuse gastric cancer. It has received IND approval from both the U.S. FDA and China’s NMPA, as well as Orphan Drug Designation (ODD) and Fast Track Designation (FTD) from the U.S. FDA. In August 2025, this drug was nominated for the Galien Award, known as the "Nobel Prize of the pharmaceutical industry." It is currently undergoing Phase I clinical trials at the Peking University Cancer Hospital. This pipeline is also the world’s first drug to be advanced to the clinical stage via an "organoid + AI" technology platform and is expected to enter Phase II clinical trials by the end of 2025.
Since its establishment at the end of 2020, Signet Therapeutics' forward-looking strategic layout of an "Organoid + AI"-powered technology system for innovative targeted cancer drug development has gained international authoritative recognition. It was featured on the homepage of the globally renowned biotech media Fierce Biotech and hailed as the "NEXT Generation" paradigm for cancer drug development. In April 2025, the U.S. FDA officially issued a statement explicitly supporting the gradual replacement of traditional animal experiments with organoid and AI technologies, fully validating the foresight and scientific rigor of the company’s technical layout from four years prior.
1
END
1
